HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...

During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research published in The Lancet medical journal. The drug lenacapavir passed a critical ...

Enormous progress has been made in tackling the global HIV epidemics over the past two decades. The number of people dying ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Sub-Saharan Africa Leads Global HIV Decline Nov. 25, 2024 — A new study reveals significant progress in the global fight against HIV/AIDS, alongside a stark warning that current trends indicate ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...